Pages that link to "Q44570712"
Jump to navigation
Jump to search
The following pages link to Fluconazole and itraconazole susceptibility of clinical isolates of Cryptococcus neoformans at a tertiary care centre in India: a need for care (Q44570712):
Displaying 21 items.
- Treatment of cryptococcosis in the setting of HIV coinfection. (Q30366117) (← links)
- Global trends in the antifungal susceptibility of Cryptococcus neoformans (1990 to 2004). (Q33859215) (← links)
- Genome-wide expression profiling of the response to short-term exposure to fluconazole in Cryptococcus neoformans serotype A (Q33898678) (← links)
- HIV-associated tuberculosis and cryptococcosis in resource-limited settings (Q36223899) (← links)
- Antifungal susceptibility of clinical and environmental Cryptococcus neoformans and Cryptococcus gattii isolates in Jabalpur, a city of Madhya Pradesh in Central India (Q36440166) (← links)
- Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: 10.5-year analysis of susceptibilities of noncandidal yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing (Q37051529) (← links)
- Antifungal susceptibilities of clinical and environmental isolates of Cryptococcus neoformans in Goiânia city, Goiás, Brazil (Q39481475) (← links)
- Molecular typing of clinical isolates of Cryptococcus neoformans/Cryptococcus gattii species complex from Northeast Mexico (Q41643640) (← links)
- Meningitis Due to Cryptococcus gattii in an Immunocompetent Patient (Q42238306) (← links)
- Pharmacokinetics of fosfluconazole and fluconazole following multiple intravenous administration of fosfluconazole in healthy male volunteers (Q42284150) (← links)
- Comparison of results of voriconazole disk diffusion testing for Candida species with results from a central reference laboratory in the ARTEMIS global antifungal surveillance program. (Q42561331) (← links)
- Terbinafine inhibits Cryptococcus neoformans growth and modulates fungal morphology (Q44092278) (← links)
- Microbiological aspects of the cryptococcosis in the post-HAART era (Q44103032) (← links)
- Antifungal drug susceptibility of Cryptococcus neoformans from clinical sources in Nairobi, Kenya (Q46421581) (← links)
- Current scenario of cryptococcosis and antifungal susceptibility pattern in India: a cause for reappraisal (Q46654930) (← links)
- Antifungal susceptibilities of Cryptococcus species complex isolates from AIDS and non-AIDS patients in Southeast China (Q46835310) (← links)
- Symptomatic relapse of HIV-associated cryptococcal meningitis after initial fluconazole monotherapy: the role of fluconazole resistance and immune reconstitution (Q50659916) (← links)
- Comparative analysis of the Vitek 2 antifungal susceptibility system and E-test with the CLSI M27-A3 broth microdilution method for susceptibility testing of Indian clinical isolates of Cryptococcus neoformans (Q50962922) (← links)
- Molecular epidemiology and antifungal susceptibility of Serbian Cryptococcus neoformans isolates. (Q54227412) (← links)
- Synthesis and Evaluation of Baylis-Hillman Reaction Derived Imidazole and Triazole Cinnamates as Antifungal Agents (Q58555610) (← links)
- Cryptococcus neoformans/gattii Species Complexes from Pre-HIV Pandemic Era Contain Unusually High Rate of Non-Wild-Type Isolates for Amphotericin B (Q90247457) (← links)